NCT04081220View on ClinicalTrials.gov

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2020

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2026

Conditions

Thrombocythemia, Essential

Interventions

DRUG

IMG-7289

Single starting dose with individualized dose titrations throughout

Trial Locations (1)

78229

Mays Cancer Center, San Antonio

All Listed Sponsors

collaborator

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04081220 - Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 | Biotech Hunter | Biotech Hunter